Aberrant and alternative splicing in cancer.
Pre-mRNA splicing is a sophisticated and ubiquitous nuclear process, which is a natural source of cancer-causing errors in gene expression. Intronic splice site mutations of tumor suppressor genes often cause exon-skipping events that truncate proteins just like classical nonsense mutations. Also, many studies over the last 20 years have reported cancer-specific alternative splicing in the absence of genomic mutations. Affected proteins include transcription factors, cell signal transducers, and components of the extracellular matrix. Antibodies against alternatively spliced products on cancer cells are currently in clinical trials, and competitive reverse transcription-PCR across regions of alternative splicing is being used as a simple diagnostic test. As well as being associated with cancer, the nature of the alternative gene products is usually consistent with an active role in cancer; therefore, the alternative splicing process itself is a potential target for gene therapy.
Venables
Julian P
JP
University of Newcastle-upon-Tyne, Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle-upon-Tyne, United Kingdom. j.venables@ncl.ac.uk
D017398:Alternative Splicing; D016326:Extracellular Matrix Proteins / Q000235:genetics; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D009369:Neoplasms / Q000209:etiology / Q000235:genetics* / Q000628:therapy; D014157:Transcription Factors / Q000235:genetics
D016326:Extracellular Matrix Proteins; D008565:Membrane Proteins; D014157:Transcription Factors